Clostridium difficile
Clostridium difficile
复制标题
DOI：
10.1016/j.cll.2017.01.007
复制
发表时间：
2017-06-01
影响因子：
1.7
通讯作者：
Curry, Scott R.
中科院分区：
文献类型：
--
作者：
Curry, Scott R.
艰难梭菌感染（cdi）已成为住院和免疫功能低下患者健康的主要威胁之一。艰难梭菌定殖的重要性越来越被人们认识到，它不仅是临床检测假阳性的来源，也是医院和其他卫生保健环境中新感染的来源。在过去的五年里，一些新的治疗策略已经完成了临床试验，包括粪便微生物群移植，这些治疗策略利用了对CDI患者微生物群改变和宿主防御的日益了解。本文重点介绍了CDI的流行病学变化、实验室诊断、发病机制和治疗。
Clostridium difficile infections (CDIs) have emerged as one of the principal threats to the health of hospitalized and immunocompromised patients. The importance of C difficile colonization is increasingly recognized not only as a source for false-positive clinical testing but also as a source of new infections within hospitals and other health care environments. In the last five years, several new treatment strategies that capitalize on the increasing understanding of the altered microbiome and host defenses in patients with CDI have completed clinical trials, including fecal micro biota transplantation. This article highlights the changing epidemiology, laboratory diagnostics, pathogenesis, and treatment of CDI.